Retatrutide

Clinical Trials

Retatrutide (LY3437943)

Aliases
LY3437943, Triple-G
Administration
Subcutaneous injection (once weekly)

Documented side effects

Tier 1 · Peer-reviewed / regulatory

Nausea

A common digestive side effect, often most noticeable when starting or increasing the dose.

Vomiting

A gastrointestinal side effect that can accompany nausea, particularly early in treatment.

Diarrhea

A gastrointestinal side effect commonly reported with this class of compound.

Long-term safety still under study

This compound is newer to human research, and its long-term safety profile is still being established.